Obesity and cardiovascular disease

Circulation

Volumn 125, Issue 9, 2012, Pages 1178-1182

  Apovian, Caroline M ^a   Gokce, Noyan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; LORCASERIN; MAZINDOL; METRELEPTIN; NALTREXONE; NEW DRUG; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BLOOD PRESSURE; BODY MASS; BRAIN HEMORRHAGE; BREAST TUMOR; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DISABLED PERSON; DISEASE ASSOCIATION; DISEASE COURSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; MALE; NONHUMAN; OBESITY; OSTEOARTHRITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN DIET; PULMONARY HYPERTENSION; RAT; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP APNEA SYNDROME; STOMACH BYPASS; STROKE; TERATOGENICITY; TRAFFIC ACCIDENT; TREATMENT INDICATION; TREATMENT OUTCOME; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; ATRIAL FIBRILLATION; BARIATRIC SURGERY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; OBESITY; PHENTERMINE; RECOVERY OF FUNCTION; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84857883645     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.022541     Document Type: Review

References (21)

1. Berrington de Gonzalez A, Hartge P, Cerhan JF, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman- Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jaquotte A, Willett WC, Thun MJ. Body mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211-2219.
2. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Haley J, Qizlbash N, Collins R, Peto R. Body mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.
3. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123:1683-1701.
4. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial function in obese subjects. Arterioscler Thromb Vasc Biol. 2008;28:1654-1659.
5. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, Meigs JB, Sutherland P, D'Agostino RB Sr, O'Donnell CJ, Fox CS. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity. 2010;18:2191-2198.
6. Pou KM, Massaro JM, Hoffmann U, Lieb K, Vasan RS, O'Donnell CJ, Fox CS. Patterns of abdominal fat distribution: the Framingham Heart Study. Diabetes Care. 2009; 32:481-485.
7. Khaodhiar L, Apovian CM. Current perspectives of obesity and its treatment. Manag Care Interface. 2007;20:24-31. (Pubitemid 46982753)
8. James WPT, Caterson ID, Coutinho W, Finer N, VanGaal LF, Maggioni AP, Torp- Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363: 905-917.
9. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161. (Pubitemid 38196725)
10. Glazer G. Long term pharmacotherapy of obesity 2000: a review of safety and efficacy. Arch Intern Med. 2001;161: 1814-1824. (Pubitemid 32762724)
11. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194-1199. (Pubitemid 350273303)
12. Ioannides-Demos L, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes. 2011; 2011:179674.
13. National Heart, Lung, and Blood Institute (NHLBI) and North American Association for the Study of Obesity (NAASO). The Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 2000. Publication No. 00-4084.
14. Powell A, Apovian CM, Aronne LJ. New targets for the treatment of obesity. Clin Pharmacol Ther. 2011;90:40-51.
15. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361: 445-454.
16. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
17. Rubino F, Kaplan LM, Schauer PR, Cummings DE; Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399-405.
18. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357: 741-752. (Pubitemid 47295641)
19. Gokce N, Vita JA, McDonnell M, Forse AR, Istfan N, Stoeckl M, Lipinska I, Keaney JF Jr, Apovian CM. Effect of medical and surgical weight loss on endothelial vasomotor function in obese patients. Am J Cardiol. 2005;95:266-268. (Pubitemid 40092098)
20. Bigornia SJ, Mott MM, Hess DT, Apovian CM, McDonnell ME, Duess MA, Kluge MA, Fiscale AJ, Vita JA, Gokce N. Long-term successful weight loss improves vascular endothelial function in severely obese individuals. Obesity. 2010;18: 754-759.
21. Owan T, Avelar E, Morley K, Jifi R, Hall N, Krezowski J, Gallagher J, Williams Z, Preece K, Gundersen N, Strong MB, Pendleton RC, Segerson N, Cloward TV, Walker JM, Farney RJ, Gress RE, Adams TD, Hunt SC, Litwin SE. Favorable changes in cardiac geometry and function following gastric bypass surgery. J Am Coll Cardiol. 2011;57:732-739.